Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to 7945.13%.

  • Cartesian Therapeutics' EBITDA Margin fell 16924200.0% to 7945.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 4395.97%, marking a year-over-year decrease of 38852700.0%. This contributed to the annual value of 199.02% for FY2024, which is 6460500.0% up from last year.
  • Cartesian Therapeutics' EBITDA Margin amounted to 7945.13% in Q3 2025, which was down 16924200.0% from 5334.9% recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' EBITDA Margin registered a high of 5334.9% during Q2 2025, and its lowest value of 7945.13% during Q3 2025.
  • Its 5-year average for EBITDA Margin is 686.66%, with a median of 73.26% in 2021.
  • In the last 5 years, Cartesian Therapeutics' EBITDA Margin crashed by -61149900bps in 2024 and then skyrocketed by 52934900bps in 2025.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' EBITDA Margin stood at 40.86% in 2021, then dropped by -15bps to 34.92% in 2022, then tumbled by -6254bps to 2149.07% in 2023, then skyrocketed by 163bps to 1352.83% in 2024, then crashed by -687bps to 7945.13% in 2025.
  • Its EBITDA Margin was 7945.13% in Q3 2025, compared to 5334.9% in Q2 2025 and 1607.09% in Q1 2025.